Track topics on Twitter Track topics that are important to you
BERKELEY, CA -- (Marketwired) -- 06/09/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Michael Ostrach, the Company's Chief Financial Officer, will present at the William Blair 35th Annual Growth Stock Conference on Thursday, June 11, 2015 at 8:00 AM Central Time at the Four Seasons Hotel in Chicago.
A live webcast of the presentation will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at:
Dynavax, a clinical-stage biopharmaceutical company, uses TLR biology to discover and develop novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine, and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information visit www.dynavax.com.Michael Ostrach Chief Financial Officer 510-665-7257 NEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...